ACP
NBRV

Acuta Capital Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Acuta Capital Partners’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,239
Closed -$2.81M – 82
2018
Q1 		$2.81M Sell
2,239
-81
-3% -$120K 0.46% 31
2017
Q4 		$3.47M Buy
2,320
+720
+45% +$1.14M 0.65% 24
2017
Q3 		$3.28M Sell
1,600
-2,183
-58% -$5.12M 0.59% 31
2017
Q2 		$9.91M Buy
3,783
+1,072
+40% +$2.76M 2.77% 10
2017
Q1 		$8.13M Sell
2,711
-115
-4% -$280K 1.93% 12
2016
Q4 		$4.21M Buy
2,826
+492
+21% +$653K 1.57% 20
2016
Q3 		$4.11M Buy
2,334
+99
+4% +$191K 1.54% 23
2016
Q2 		$4.19M Buy
2,235
+55
+3% +$111K 2.01% 16
2016
Q1 		$4.88M Buy
2,180
+529
+32% +$1.14M 2.73% 12
2015
Q4 		$3.97M Buy
1,651
+246
+18% +$600K 1.9% 20
2015
Q3 		$3.34M Buy
+1,405
New +$3.72M 1.93% 16

Other funds holding NBRV

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return

Acuta Capital Partners's NBRV Position: Q2 2018 in Review

Acuta Capital Partners sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2018, closing a stake of 2,239 shares — an estimated $2.81M sold.

Acuta Capital Partners first reported a position in NBRV in Q3 2015 and held it in 11 quarters. The position peaked at $9.91M in Q2 2017. 42 funds tracked by Wall St. Rank hold NBRV as of Q2 2018.

  • Acuta Capital Partners reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 2,239 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2018, an estimated $2.81M.
  • Acuta Capital Partners first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 11 quarters.
  • Acuta Capital Partners's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $9.91M in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2018.

Based on Acuta Capital Partners's 13F filing for Q2 2018, filed 15 Aug 2018.